-
公开(公告)号：US11746098B2
公开(公告)日：2023-09-05
申请号：US17133362
申请日：2020-12-23
发明人： Matthew Cullen , Sheila Hauck , Megan Foley , Bradley Tait , Markus Haeberlein
IPC分类号： C07D401/06 , C07D207/333 , C07D207/335 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/12
CPC分类号： C07D401/06 , C07D207/333 , C07D207/335 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/12
摘要： The present invention is directed to compounds that inhibit Usp14, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
-
公开(公告)号：US20200308198A1
公开(公告)日：2020-10-01
申请号：US16902019
申请日：2020-06-15
发明人： Matthew Cullen , Sheila Hauck , Bolin Geng , Megan Foley , Cecilia M. Bastos , Benito Munoz , Markus Haeberlein , Bradley Tait
IPC分类号： C07F7/18 , C07D401/14 , C07D401/06 , C07D403/06 , C07D471/04 , C07D209/12 , C07B59/00 , C07D209/14 , C07D417/14 , C07D519/00
摘要： The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
-
公开(公告)号：US10738011B2
公开(公告)日：2020-08-11
申请号：US15539401
申请日：2015-12-23
发明人： Cecilia M. Bastos , Benito Munoz , Bradley Tait
IPC分类号： C07D231/14 , C07D249/06 , C07D413/12 , C07D403/12 , C07D405/12 , A61P11/00 , A61K31/415 , A61K31/4155 , A61K31/4178 , A61K31/5377 , A61K45/06 , G01N33/68
摘要： The present disclosure is based, in part, on the discovery that disclosed compounds such as those having Formula (IVa), (Va), (IV), or (V) can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
-
公开(公告)号：US10392372B2
公开(公告)日：2019-08-27
申请号：US15539392
申请日：2015-12-23
发明人： Cecilia M. Bastos , Benito Munoz , Bradley Tait
IPC分类号： A61K31/42 , A61K45/06 , G01N33/50 , A61K31/422 , A61K31/433 , C07D261/18 , C07D307/54 , C07D307/68 , C07D405/12 , C07D407/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , A61K31/4245 , A61K31/5377
摘要： The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
-
公开(公告)号：US20170369480A1
公开(公告)日：2017-12-28
申请号：US15539392
申请日：2015-12-23
发明人： Cecilia M. Bastos , Benito Munoz , Bradley Tait
IPC分类号： C07D413/12 , C07D417/12 , C07D413/14 , C07D409/14 , C07D307/68 , C07D261/18 , A61K45/06 , A61K31/5377 , A61K31/433 , A61K31/4245 , A61K31/422 , G01N33/50 , A61K31/42
CPC分类号： C07D413/12 , A61K31/42 , A61K31/422 , A61K31/4245 , A61K31/433 , A61K31/5377 , A61K45/06 , C07D261/18 , C07D307/54 , C07D307/68 , C07D405/12 , C07D407/12 , C07D409/14 , C07D413/14 , C07D417/12 , G01N33/502 , G01N33/5044
摘要： The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
-
公开(公告)号：US20150166567A1
公开(公告)日：2015-06-18
申请号：US14333957
申请日：2014-07-17
发明人： Robert J. Chambers , Megan Foley , Bradley Tait
IPC分类号： C07D495/14
CPC分类号： C07D495/14 , A61K45/06
摘要： The present invention is directed to compounds having the Formula (I), (Ia) or (Ib), compositions thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis.
摘要翻译： 本发明涉及具有式（I），（Ia）或（Ib）的化合物，其组合物和用于治疗与蛋白质降解功能障碍相关的病症的方法。
-
公开(公告)号：US11098035B2
公开(公告)日：2021-08-24
申请号：US16510406
申请日：2019-07-12
发明人： Cecilia M. Bastos , Benito Munoz , Bradley Tait
IPC分类号： C07D413/12 , A61K31/42 , A61K31/4245 , C07D413/14 , C07D409/14 , C07D417/12 , C07D261/18 , C07D307/54 , C07D405/12 , C07D407/12 , A61K31/422 , A61K31/433 , A61K31/5377 , A61K45/06 , C07D307/68 , G01N33/50
摘要： The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
-
公开(公告)号：US20200299270A1
公开(公告)日：2020-09-24
申请号：US16691390
申请日：2019-11-21
发明人： Megan Foley , Bradley Tait , Matthew Cullen
IPC分类号： C07D403/06 , C07D207/333 , C07D207/337 , C07D231/12 , C07D249/06 , C07D263/32 , C07D275/02 , C07D295/185 , C07D333/20 , C07D401/06 , C07D405/06 , C07D471/04 , C07D333/22
摘要： The present invention is directed to compounds having the Formulae (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX), pharmaceutically acceptable salts, prodrugs and solvates thereof, compositions of any of thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis comprising an effective amount of these compounds.
-
公开(公告)号：US10738040B2
公开(公告)日：2020-08-11
申请号：US16190964
申请日：2018-11-14
发明人： Cecilia M. Bastos , Benito Munoz , Bradley Tait
IPC分类号： C07D261/08 , C07D413/12 , C07F7/18 , C07D413/14 , C07D231/12 , C07D233/61 , C07D417/12 , C07D261/18 , C07D285/12 , A61K31/16 , A61K31/42 , A61K31/422 , A61K31/4245 , A61K31/433 , A61K31/695 , A61K45/06 , C07C243/36
摘要： The present disclosure features disclosed compounds which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound.
-
公开(公告)号：US20180147187A1
公开(公告)日：2018-05-31
申请号：US15542997
申请日：2006-01-12
发明人： Cecilia M. Bastos , Benito Munoz , Bradley Tait
IPC分类号： A61K31/422 , A61K31/7028 , A61K31/4709 , A61K31/4025 , A61K31/433 , A61K31/42 , A61K31/4245 , A61P11/00
CPC分类号： A61K31/422 , A61K31/33 , A61K31/4025 , A61K31/42 , A61K31/421 , A61K31/4245 , A61K31/433 , A61K31/4709 , A61K31/7028 , A61P11/00 , C07D261/18 , C07D413/12 , C07D417/12 , A61K2300/00
摘要： The present disclosure features compounds such as those having the Formulae (IIa), (IIb), (IIc), (IId), (IIIa), and (IIIb), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound, such as a compound of Formula (IIa), (IIb), (IIc), (IId), (IIIa), or (IIIb).
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.024 秒)
